secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cabaletta Bio, Inc. (CABA)
CIK:        0001759138
Form:       8-K
Filed at:   2026-05-14T11:02:18+00:00
Accession:  0001759138-26-000024
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Cabaletta Bio presents preconditioning-free clinical data and automated manufacturing data for rese-cel at ASGCT 2026
--------------------------------------------------------------------------------

- Two of four pemphigus vulgaris patients at lowest PC-free dose maintained drug-free responses through 6 months.
- No dose-limiting toxicities or neurotoxicity; one patient had grade 1 cytokine release syndrome.
- First two autoimmune patients dosed with rese-cel manufactured on Cell Shuttle met all release specs with similar PK/PD.
- Higher-dose PC-free data expected 2H26; initial SLE data at lowest dose expected 1H26 at EULAR 2026 Congress.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1759138/000175913826000024/0001759138-26-000024-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1759138/000175913826000024/caba-20260514.htm
  HTML page:      https://secwatch.observer/filing/0001759138-26-000024

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer